Hundreds of millions of people are infected with hepatitis B virus (HBV) worldwide. These individuals face an increased risk of serious consequences of chronic hepatitis B (CHB), such as liver cirrhosis and hepatocellular carcinoma. Fortunately, there are effective antiviral therapies that can do much to reduce the morbidity and mortality associated with CHB. Unfortunately, despite the availability of these treatments, many patients go undiagnosed and untreated for CHB and needlessly suffer CHB-related health issues. These treatment gaps exist, especially in populations and areas with a high prevalence of HBV infection, because many clinicians are not fully aware of the data supporting the diagnosis, monitoring and treatment of CHB and the guidance contained in the CHB treatment guidelines. This program has been designed to address these professional practice gaps.
National thought leaders lead this program using case-based panel discussions to drive home key messages regarding HBV diagnosis, monitoring and treatment while discussing barriers unique to different ethnic communities. Presenters will discuss transmission of HBV in various populations; symptoms of HBV infection; long-term risk and consequences of untreated HBV infection; major treatment guidelines for the diagnosis and management of patients with HBV infection; and the treatment of special populations of patients with HBV infection so that more patients can be screened or tested for HBV and receive the full benefit of available treatments for CHB, leading to decreased morbidity and mortality.
| Paul Kwo, MD Associate Professor of Medicine, Medical Director, Liver Transplantation Division of Gastroenterology and Hepatology Indiana University School of Medicine Indianapolis, Indiana |
Mark Sulkowski, MD Associate Professor of Medicine, Medical Director, Viral Hepatitis Center Johns Hopkins University School of Medicine Baltimore, Maryland |
|
Tram Tran, MD Medical Director, Liver Transplantation Cedars-Sinai Medical Center Associate Professor, University of California, Los Angeles Los Angeles, California |
|
Albert Min, MD
Calvin Pan, MD |
Lennox Jeffers, MD
Son Do, MD |
The target audience for this program is all health care providers who care for patients with HBV infection, including physicians, nurse practitioners, physician assistants, and nurses.
Supported by an independent educational grant from Gilead Sciences Medical Affairs.
Upon completion of the program, participants should be able to:
Discuss how the hepatitis B virus (HBV) is transmitted in various populations;
Describe the symptoms of HBV infection;
Identify the long-term risk and consequences of untreated HBV infection;
Review the various major treatment guidelines for the diagnosis and management of patients with HBV infection;
Discuss the relative advantages and disadvantages of various antiviral treatments available for patients with HBV infection;
Describe the treatment of special populations of patients with HBV infection.
Release Date: June 15, 2011
Expiration Date: June 15, 2012
Estimated time to complete the Real Cases in HBV Online Program: 4 hours
Media: Internet
Contracted Research: Merck; Genentech/Roche; Vertex; Gilead; Boehringer Ingelheim; Tibotec
Consulting Fees: Merck; Genentech/Roche; Vertex; Gilead; Boehringer Ingelheim; Anadys; Tibotec; Human Genome Sciences
Advisory Board: Pfizer; Pharmasett
Dr. Paul Kwo:
Contracted Research: Schering Plough/Merck; Novartis; GSK; Echosens; Vertex; Gilead; Quest
Consulting Fees: Gilead; Echosens; Biogen; GSK; Vertex; Novartis; Idera Pharmaceuticals; Boehringer Ingelheim; HGS; Biolex; Fibrogen; Ligand; Schering Plough/Merck
Dr. Tram Tran:
Contracted Research: Roche; Gilead; Vertex
Advisory Boards: Salix; Roche
Board Membership: American Board of Internal Medicine
Dr. Lennox Jeffers:
Contracted Research: Merck & Co.; GlaxoSmithKline; Zymogenetics
Fees for Non-CME/CE Services: Bristol-Myers Squibb; Roche; Gilead; Vertex
Dr. Albert Min:
Contracted Research: Bristol-Myers Squibb; Gilead
Consulting Fees: Bristol-Myers Squibb; Gilead
Fees for Non-CME/CE Services: Bristol-Myers Squibb; Gilead
Dr. Calvin Pan:
Contracted Research: Bristol-Myers Squibb; Gilead
Consulting Fees: Bristol-Myers Squibb; Gilead; Genentech
Fees for Non-CME/CE Services: Bristol-Myers Squibb; Gilead; Genentech; Salix; Three Rivers
Dr. Son Do:
Contracted Research: Centacor
Consulting Fees: Bristol-Myers Squibb; Gilead; Vertex
Fees for Non-CME/CE Services: Bristol-Myers Squibb; Gilead
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following planners and managers, Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Julia Kimball, RN, BSN; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine (PIM), ViralEd, Inc. and Gilead Sciences. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Postgraduate Institute for Medicine, ViralEd, Inc. and Gilead Sciences. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
There are no fees for participating and receiving credit for this activity. During the period, June 15, 2011 through June 15, 2012 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and evaluation form.
To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on the Submit Post-test at the bottom of the page. Your post-test will automatically be graded.
If you successfully complete the post-test (score of 70% or higher). your certificate will be made available immediately. Click on View Certificate and print the certificate for your records. If you received a score of 69% or less, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful.
You may complete the post-test online at: http://www.cmeuniversity.com/
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 |
 |
